Financial Performance - The company's operating revenue for the first half of 2020 was approximately ¥607.93 million, a decrease of 18.73% compared to ¥748.00 million in the same period last year[17]. - Net profit attributable to shareholders increased by 30.46% to approximately ¥85.07 million, up from ¥65.21 million in the previous year[17]. - The net profit after deducting non-recurring gains and losses was approximately ¥64.95 million, reflecting a growth of 10.12% compared to ¥58.98 million in the same period last year[17]. - The basic earnings per share rose to ¥0.95, a 31.94% increase from ¥0.72 in the previous year[17]. - The total assets at the end of the reporting period were approximately ¥1.40 billion, an increase of 0.76% from ¥1.38 billion at the end of the previous year[17]. - The net assets attributable to shareholders decreased by 0.53% to approximately ¥960.05 million from ¥965.13 million at the end of the previous year[17]. - The net cash flow from operating activities was approximately ¥101.96 million, an increase of 4.84% compared to ¥97.25 million in the same period last year[17]. - The weighted average return on net assets improved to 8.57%, up from 7.01% in the previous year, indicating better efficiency in utilizing equity[17]. Revenue and Sales - The company achieved operating revenue of CNY 607.93 million, a decrease of 18.73% compared to the same period last year[29]. - The company realized operating profit of CNY 109.77 million, an increase of 30.64% year-on-year[29]. - The company reported a 45.84% increase in sales of α-keto acid raw materials, totaling 56.81 tons during the reporting period[39]. - Sales of the core product, benazepril hydrochloride tablets, reached 17.34 million boxes, a growth of 23.30% year-on-year[39]. - Domestic sales accounted for 98.10% of total revenue, totaling ¥596,354,435.94, while international sales decreased by 42.71% to ¥11,573,865.19[44]. Research and Development - The company emphasizes R&D as a core development driver and aims to develop high-quality products with clinical value[29]. - Research and development expenses increased by 72.27% to ¥18,225,402.83, reflecting a significant investment in R&D activities[42]. - The company initiated the construction of a new R&D center in Hangzhou, focusing on integrating and recruiting R&D personnel[38]. - The company received patent authorization for "Mosapride Citrate Tablets and their preparation methods" during the reporting period[38]. Investment and Assets - The company increased its long-term equity investments by 37.97%, primarily due to increased investments in joint ventures[31]. - Inventory increased by 35.38% compared to the beginning of the period, mainly due to an increase in raw material stock[31]. - The total investment amount during the reporting period was CNY 145,151,415.46, representing a significant increase of 299.66% compared to the previous year[52]. - The company has a total of CNY 2,766,132.20 in restricted cash due to pledges[51]. Risks and Challenges - The company highlighted risks including macroeconomic fluctuations and regulatory changes that could impact future performance[4]. - The company anticipates potential risks from macroeconomic fluctuations due to the pandemic, which may impact production and operations[77]. - Regulatory risks are increasing in the pharmaceutical industry, necessitating timely adjustments to business strategies to comply with new policies[78]. - Rising production costs are a concern, driven by stricter safety and environmental regulations, as well as increasing labor and material costs[79]. Shareholder and Stock Information - The company plans not to distribute cash dividends or issue bonus shares for this reporting period[4]. - The closing price of the company's stock has been below the issue price for 20 consecutive trading days, which will automatically extend the lock-up period by 6 months[91]. - The company commits that within 12 months after the lock-up period, it will not transfer more than 20% of the shares held prior to the public offering[92]. - The company will ensure compliance with regulations from the China Securities Regulatory Commission regarding shareholder reductions[92]. Environmental Compliance - The company has established wastewater treatment facilities with a design capacity of 1,000 tons per day at both its headquarters and Jiangsu Yuexin, ensuring stable compliance with discharge standards[128]. - The company has implemented a comprehensive environmental monitoring plan, conducting self-inspections and third-party monitoring to ensure compliance with environmental regulations[135]. - The company has a solid waste storage facility that complies with national pollution control standards, ensuring proper management of hazardous and general solid waste[131]. Legal and Compliance - The company reported a litigation case with Taizhou Shangyao Pharmaceutical Co., Ltd., involving an amount of 236,600 yuan, and the company won the case, which is currently being executed[105]. - The company has committed to ensuring the effective use of raised funds and maintaining shareholder rights[102]. - The company has made unconditional and irrevocable commitments regarding the compensation for any misleading statements or omissions[102]. Future Outlook - The company provided a future outlook, projecting a revenue growth of 25% for the second half of 2020, driven by new product launches and market expansion[94]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2021[94]. - A strategic acquisition of a local biotech firm was announced, expected to enhance the company's product pipeline and market reach[94].

证券代码：002940 证券简称：昂利康 公告编号：2020-037 浙江昂利康制药股份有限公司 关于参加浙江辖区上市公司投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 为进一步加强与投资者特别是中小投资者的沟通交流，浙江昂利康制药股份 有限公司（以下简称"公司"）将参加由中国证券监督管理委员会浙江监管局指导、 浙江上市公司协会与深圳市全景网络有限公司共同举办的"凝心聚力 共克时艰" 辖区上市公司投资者网上集体接待日主题活动，现将有关事项公告如下： 本次投资者网上集体接待日活动将通过深圳市全景网络有限公司提供的网 上平台举行，投资者可以登录"全景·路演天下"网站（http://rs.p5w.net）参与公 司本次投资者网上接待日活动。网上互动交流时间为 2020 年 5 月 15 日（星期五） 下午 15:00-17:00。 届时公司总经理蒋震山先生、财务总监杨晓慧女士、副总经理兼董事会秘书 孙黎明先生将与投资者通过网络在线交流形式就公司治理、经营发展状况等投资 者关心的问题进行沟通与交流（如有特殊情况，参与人员会有调整）。 欢 ...

Financial Performance - The company's operating revenue for Q1 2020 was ¥305,801,306.93, a decrease of 20.11% compared to the same period last year[7] - Net profit attributable to shareholders was ¥41,793,775.21, representing an increase of 24.36% year-over-year[7] - Basic earnings per share rose to ¥0.46, up 24.32% from ¥0.37 in the same quarter last year[7] - The total profit for the first quarter was CNY 51,962,956.43, compared to CNY 41,846,834.56 in the previous year, marking an increase of approximately 24.5%[41] - The net profit for the first quarter increased to CNY 44,118,468.41, up from CNY 35,714,800.96 year-over-year, representing a growth of approximately 23.5%[41] Cash Flow - The net cash flow from operating activities increased by 101.07% to ¥103,085,670.64 compared to the previous year[7] - Cash generated from operating activities increased by 101.07% to ¥103,085,670.64 from ¥51,268,440.11, mainly due to reduced payments for raw materials[18] - The cash inflow from operating activities was CNY 418,141,711.73, a decrease from CNY 532,548,208.57 in the previous period, reflecting a decline of approximately 21.5%[48] - The cash flow from operating activities net amount was CNY 102,385,716.96, a significant increase from CNY 21,689,591.81 in the previous period[52] - The cash inflow from sales of goods and services was CNY 352,203,535.43, compared to CNY 474,238,226.03 in the previous period, reflecting a decrease of approximately 25.7%[48] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,466,810,856.78, reflecting a growth of 5.91% from the end of the previous year[7] - Total liabilities rose to CNY 406,133,881.44, up from CNY 368,512,617.20, indicating an increase of about 10.2%[33] - The total equity attributable to shareholders reached CNY 1,007,004,875.95, compared to CNY 965,125,415.82, reflecting an increase of approximately 4.3%[34] - The company’s inventory stood at CNY 139,004,353.59, indicating a stable supply chain management[56] Investments and Expenses - R&D expenses increased by 82.31% to ¥10,435,352.69 from ¥5,724,034.56, reflecting higher investment in research and development[16] - Long-term equity investments rose by 39.33% to ¥33,088,908.53 from ¥23,748,998.08 due to increased investments in joint ventures[15] - The company reported an investment income of CNY 441,990.36, recovering from a loss of CNY 1,294,056.18 in the previous period[40] - The management expenses increased to CNY 14,851,817.16 from CNY 10,853,678.39, reflecting higher administrative costs[40] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 6,534[11] - The largest shareholder, Shenzhou Juntai Investment Co., Ltd., held 37.78% of the shares[11] - The company did not engage in any repurchase transactions during the reporting period[12] Government Support and Future Plans - Government subsidies received totaled ¥35,857,867, with ¥33,300,871 being temporary funds[19] - The company plans to raise up to ¥560 million through a non-public stock issuance, pending shareholder approval[19] Changes in Accounting Standards - The first quarter report for 2020 was not audited, which may affect the reliability of the financial data presented[61] - The company has implemented new revenue and lease standards starting in 2020, which may impact future financial reporting[60]

Financial Performance - The company's operating revenue for 2019 was CNY 1,396,193,906.33, representing an increase of 11.25% compared to CNY 1,255,047,658.50 in 2018[16]. - The net profit attributable to shareholders for 2019 was CNY 112,269,989.60, a growth of 3.29% from CNY 108,697,464.69 in 2018[16]. - The net profit after deducting non-recurring gains and losses increased by 20.52% to CNY 103,964,289.05 from CNY 86,265,739.19 in 2018[16]. - The net cash flow from operating activities rose significantly by 59.79% to CNY 213,493,104.11 compared to CNY 133,612,108.47 in 2018[16]. - The basic earnings per share decreased by 18.30% to CNY 1.25 from CNY 1.53 in 2018[17]. - The total assets at the end of 2019 were CNY 1,384,985,439.21, reflecting a decrease of 5.80% from CNY 1,470,201,183.43 at the end of 2018[17]. - The net assets attributable to shareholders increased by 5.01% to CNY 965,125,415.82 from CNY 919,067,528.47 in 2018[17]. - The company achieved total revenue of ¥1,396,193,906.33, representing a year-on-year growth of 11.25%[30]. - Operating profit increased to ¥155,103,090.28, reflecting an 18.18% year-on-year growth[30]. - The company reported a total revenue of 1.5 billion RMB for the fiscal year 2019, representing a year-over-year growth of 20%[111]. Profit Distribution - The company reported a profit distribution plan of 10 RMB per 10 shares for a total of 90,000,000 shares, with no bonus shares issued[5]. - The total cash dividend distributed for 2019 was RMB 90 million, which accounted for 100% of the distributable profit of RMB 363.47 million[110]. - The cash dividend per 10 shares was set at RMB 10.00 (including tax)[110]. - The profit distribution plan was based on the total share capital as of December 31, 2019, which was 90 million shares[110]. - The company did not propose any stock dividends or capital reserve transfers for 2019, maintaining a total share capital of 90 million shares[110]. Research and Development - The company is focused on new product development and has ongoing research in innovative drugs, particularly in the field of antibiotics[10]. - The company emphasizes R&D and innovation, focusing on high-value products in the fields of anti-infection, cardiovascular, and kidney diseases[32]. - Research and development expenses for the year amounted to 37,347,141.06 yuan, a decrease of 19.18% compared to the previous year[57]. - The company achieved a 18.31% increase in sales expenses, totaling 765,204,177.14 yuan in 2019[57]. - The company plans to ensure the R&D progress of key products, targeting specific drug evaluations and registrations[86]. - The company aims to enhance its R&D capabilities and optimize product layout, focusing on both raw materials and formulations as part of its dual-driven strategy[84]. - Research and development efforts focused on two new drug candidates, with a projected investment of 200 million RMB over the next two years[111]. Market Expansion and Strategy - The company aims to expand its market presence and is exploring potential mergers and acquisitions to enhance growth[10]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2021[111]. - The company anticipates industry consolidation and transformation due to ongoing healthcare reforms and the implementation of new drug management laws[83]. - The company will focus on core product categories and optimize marketing strategies to seize development opportunities in 2020[85]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[114]. Risk Management - The company emphasizes the importance of risk factors including macroeconomic fluctuations and rising production costs, which could impact future performance[5]. - The company is preparing for potential changes in industry regulations that may affect its operations and strategic direction[5]. - The company is addressing the risk of rising production costs due to stricter national safety and environmental policies[94]. - The company is enhancing its compliance operations by improving internal control management and establishing a compliance culture to mitigate operational risks[89]. Corporate Governance - The company has established a comprehensive corporate governance structure to protect the rights of shareholders and creditors, ensuring fair and transparent communication[154]. - The company emphasizes employee rights protection, providing a harmonious work environment and adhering to labor laws[156]. - The company has a commitment to research and development, as evidenced by its recognition in scientific awards, which may drive future product offerings[199][200]. - The company has implemented measures to link the compensation system to the execution of return compensation measures, promoting accountability among the board and compensation committee[121]. Environmental Responsibility - The company adheres to strict environmental regulations, achieving compliance with wastewater discharge standards and obtaining ISO14001 certification[158]. - The company has established a sound risk control system for environmental protection, ensuring stable and compliant emissions from its facilities[166]. - The company has noise control measures in place, with all monitored noise levels meeting the required standards[168]. - The company invested CNY 40 million in a cooperation development contract with three pharmaceutical companies for the research and registration of Buvasitan raw materials and formulations[172]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 12,665, an increase from 6,534 at the end of the previous month[182]. - The largest shareholder, Shenzhou JunTai Investment Co., Ltd., holds 37.78% of the shares, totaling 34,000,000 shares[182]. - The company has a total of 24,750,000 restricted shares at the beginning of the period, with 19,950,000 shares released during the period, leaving 4,800,000 restricted shares at the end[180]. - The company’s major shareholders include several individuals, with Zhao Chengjian holding 2.49% (2,244,722 shares) and Wu Weihua holding 2.37% (2,128,570 shares)[182].

证券代码：002940 证券简称：昂利康 公告编号：2019-038 浙江昂利康制药股份有限公司 关于参加浙江辖区上市公司投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 为进一步加强与投资者的沟通交流，浙江昂利康制药股份有限公司（以下简 称"公司"）将参加由中国证券监督管理委员会浙江监管局指导、浙江上市公司协 会与深圳市全景网络有限公司共同举办的"沟通促发展、理性共成长"辖区上市公 司投资者网上集体接待日主题活动，现将有关事项公告如下： 本次投资者网上集体接待日活动将通过深圳市全景网络有限公司提供的网 上平台举行，投资者可以登录"全景·路演天下"网站（http://rs.p5w.net）参与公 司本次投资者网上接待日活动。网上互动交流时间为 2019 年 11 月 5 日（星期二） 下午 15:30-17:00。 届时公司董事长方南平先生、财务总监杨晓慧女士、副总经理兼董事会秘书 孙黎明先生及相关工作人员将与投资者通过网络在线交流形式就公司治理、经营 发展状况等投资者关心的问题进行沟通与交流。（如有特殊情况，参与人员会有 调整） ...

Financial Performance - Operating revenue for the reporting period was CNY 319,028,266.62, representing a year-on-year increase of 17.61%[7] - Net profit attributable to shareholders was CNY 25,196,811.72, an increase of 71.32% compared to the same period last year[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 24,778,643.97, up 79.25% year-on-year[7] - Basic earnings per share for the reporting period were CNY 0.28, an increase of 27.27% compared to the same period last year[7] - The company reported a net profit increase, with undistributed profits rising to CNY 334,777,715.61 from CNY 302,584,350.42, an increase of 10.6%[38] - The net profit for the third quarter was CNY 30,237,455.39, compared to CNY 16,476,265.98 in the previous year, indicating an increase of about 83.5%[42] - The total profit for the third quarter reached CNY 37,449,761.29, significantly higher than CNY 19,211,755.17 in the previous year, marking an increase of approximately 95.1%[44] - The company achieved a net profit of CNY 33,805,184.12 for the year-to-date period, compared to CNY 19,607,826.45 in the previous year, indicating an increase of about 72.2%[46] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,331,418,593.29, a decrease of 9.44% compared to the end of the previous year[7] - Total assets decreased to ¥1,331,418,593.29 from ¥1,470,201,183.43, reflecting a reduction in current assets[31] - Total liabilities decreased to CNY 205,082,083.03 from CNY 381,842,505.59, a decline of 46.3%[37] - The equity attributable to shareholders increased to CNY 1,033,463,212.06 from CNY 1,000,973,676.39, reflecting a growth of 3.2%[38] - Total liabilities reached CNY 499,274,354.53, with current liabilities at CNY 486,367,408.77 and non-current liabilities at CNY 12,906,945.76[67] - The total liabilities to equity ratio is approximately 0.51, indicating a balanced capital structure[67] Cash Flow - The net cash flow from operating activities was CNY 40,143,837.39, a decrease of 6.63% compared to the same period last year[7] - Cash flow from operating activities increased by 45.87% to ¥137,396,281.17 from ¥94,192,950.04, driven by higher cash receipts from sales[19] - Operating cash inflow for Q3 2019 was CNY 1,392,255,965.34, an increase from CNY 1,126,003,071.52 in Q3 2018, representing a growth of approximately 23.7%[57] - The company reported a net cash flow from operating activities of CNY 137,396,281.17, up from CNY 94,192,950.04 in Q3 2018, representing a growth of approximately 46%[57] Shareholder Information - The total number of shareholders at the end of the reporting period was 13,246[11] - The largest shareholder, Shenzhou Juntai Investment Co., Ltd., held 37.78% of the shares[11] Expenses - The company reported a significant increase in management expenses by 44.61% to ¥48,129,120.58 from ¥33,283,143.89, mainly due to losses from subsidiary upgrades[17] - Total operating costs for Q3 2019 were CNY 280,680,452.35, up from CNY 253,549,180.70, reflecting a year-over-year increase of 10.7%[40] - The company reported a significant reduction in sales expenses, which were CNY 43,025,794.59 compared to CNY 155,593,433.63 in the previous year, a decrease of about 72.4%[44] - Research and development expenses decreased to CNY 6,696,827.25 from CNY 11,631,064.65, a reduction of 42.3% year-over-year[40] Non-Recurring Gains and Losses - The company reported a total of CNY 6,646,090.62 in non-recurring gains and losses for the year-to-date[8] - The company reported an investment loss of CNY 3,690,494.22 for the year-to-date period, compared to a loss of CNY 96,317.17 in the previous year[47] Financial Standards - The company executed new financial accounting standards starting January 1, 2019, adjusting "available-for-sale financial assets" to "other non-current financial assets"[68] - The company has implemented new financial accounting standards since January 1, 2019, affecting the reporting of financial assets[74]

Financial Performance - The company's operating revenue for the first half of 2019 was approximately ¥748 million, representing a 21.89% increase compared to ¥614 million in the same period last year[17]. - The net profit attributable to shareholders decreased by 22.83% to approximately ¥65 million, down from ¥84 million in the previous year[17]. - The net cash flow from operating activities increased significantly by 89.95% to approximately ¥97 million, compared to ¥51 million in the same period last year[17]. - Basic and diluted earnings per share fell by 42.40% to ¥0.72, down from ¥1.25 in the previous year[17]. - The total assets at the end of the reporting period were approximately ¥1.377 billion, a decrease of 6.35% from ¥1.470 billion at the end of the previous year[17]. - The net profit attributable to shareholders was RMB 65,207,423.90, a decrease of 22.83% compared to the same period last year[34]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 58,979,501.03, down 9.96% year-on-year[34]. - The decline in net profit was primarily due to a decrease in gross profit from the cephalosporin raw material business and delays in some orders from the subsidiary, Angli Tai[34]. - The company's revenue for the reporting period reached ¥748,001,844.42, representing a year-on-year increase of 21.89% compared to ¥613,659,443.69 in the previous year[41]. - The sales of formulations amounted to ¥557,848,199.17, which is a 25.87% increase from ¥443,197,414.37 in the same period last year[43]. Research and Development - The company continues to enhance its R&D capabilities, focusing on the consistency evaluation of generic drugs and strategic product pipelines in the fields of anti-infection, cardiovascular, and kidney diseases[35]. - A patent for "a preparation method of α-keto phenylalanine calcium" was granted, and seven products completed drug re-registration[35]. - The registration applications for the consistency evaluation of Cefaclor sustained-release tablets and Amlodipine Besylate tablets have been accepted by the National Medical Products Administration[35]. - The company is focusing on expanding its market presence and enhancing its product offerings through research and development initiatives[5]. - The company is committed to improving its R&D capabilities and will establish new R&D centers to enhance innovation and project risk management[78]. Financial Management - The company plans not to distribute cash dividends or issue bonus shares for the reporting period[5]. - Cash and cash equivalents at the end of the reporting period increased by 572.78% to ¥592,554,716.39, representing 43.04% of total assets, compared to 10.18% in the same period last year[46]. - Accounts receivable decreased by 5.57% to ¥179,450,204.42, accounting for 13.03% of total assets, down from 18.60% year-on-year[46]. - Inventory decreased by 8.82% to ¥150,940,937.89, representing 10.96% of total assets, compared to 19.78% in the previous year[46]. - Short-term borrowings decreased by 100% to ¥0, as the company repaid bank loans during the reporting period[46]. - The company reported a total cash outflow from financing activities of ¥82,533,842.59 in the first half of 2019, compared to ¥30,543,737.63 in the same period of 2018, indicating a significant increase in cash outflow[175]. Market and Sales Strategy - Domestic sales accounted for 97.30% of total revenue, amounting to ¥727,799,156.27, a 20.80% increase from the previous year[43]. - International sales increased by 80.95% to ¥20,202,688.15, driven by higher export revenue from raw materials[43]. - The company implemented a new marketing system focusing on "deep distribution + refined academic promotion," resulting in a sales increase of 25.87% for formulations[36]. - The company plans to increase its marketing budget by 30% to support the launch of new products and enhance brand visibility[89]. - A strategic acquisition of a local biotech firm is in progress, which is anticipated to enhance the company's R&D capabilities and add 200 million CNY in annual revenue[89]. Risk Management - The company highlighted risks related to industry regulation, production costs, and the need for new product development in its forward-looking statements[5]. - The company faces risks from industry regulations and policy changes, which may increase operational costs and adversely affect performance if strategies are not adjusted accordingly[74]. - Rising production costs are anticipated due to increases in raw material prices, labor, and energy costs, prompting the company to optimize procurement processes and enhance production efficiency[77]. - New product development faces risks due to stringent regulatory requirements and lengthy approval processes, which could lead to increased operational costs if products are not accepted by the market[78]. - Environmental and safety risks are present due to the nature of the chemical pharmaceutical industry, necessitating ongoing investments in safety and compliance to avoid penalties and operational disruptions[79]. Shareholder and Governance - The company commits to not transferring or entrusting others to manage shares for 36 months from the date of stock issuance[87]. - The company has established a compensation fund to reimburse investors for losses incurred due to false statements in the prospectus, with a commitment to communicate and compensate affected investors[95]. - The company will refund investors who paid for shares if the prospectus is found to contain false information before the shares are listed[95]. - The company has made unconditional and irrevocable commitments regarding the implementation of return compensation measures[99]. - The company will ensure that future stock incentive plans are linked to the execution of return compensation measures[99]. Environmental Compliance - The company operates a wastewater treatment facility with a design capacity of 1,000 tons per day, which has been functioning normally during the reporting period[122]. - The company has a waste gas treatment facility with a capacity of 20,000 cubic meters per hour, ensuring compliance with relevant emission standards[123]. - The company has implemented strict monitoring and management of emissions, ensuring all facilities operate within compliance[123]. - The company adheres to specific accounting policies for bad debt provisions, fixed asset depreciation, and revenue recognition[199]. General Company Information - The company operates in the pharmaceutical manufacturing industry, focusing on drug production and sales, as well as chemical raw materials[195]. - The financial statements have been approved by the company's board of directors on August 22, 2019, ensuring compliance with accounting standards[196]. - The company has no significant doubts regarding its ability to continue as a going concern for the next 12 months[198]. - The company includes seven subsidiaries in its consolidated financial statements, reflecting a broad operational scope[196].

浙江昂利康制药股份有限公司 2019 年第一季度报告全文 浙江昂利康制药股份有限公司 2019 年第一季度报告 2019 年 04 月 1 浙江昂利康制药股份有限公司 2019 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人方南平、主管会计工作负责人杨晓慧及会计机构负责人(会计主 管人员)周德熙声明：保证季度报告中财务报表的真实、准确、完整。 2 浙江昂利康制药股份有限公司 2019 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 382,793,111.86 | 267,098,590.89 | 43.32% | | 归属于上市公司股东的净利润（元） | 33,607,604.94 | 33, ...

Financial Performance - The company's operating revenue for 2018 was CNY 1,255,047,658.50, representing a year-over-year increase of 43.74% compared to CNY 871,580,994.05 in 2017[17]. - The net profit attributable to shareholders for 2018 was CNY 108,697,464.69, which is a 7.53% increase from CNY 101,085,352.47 in 2017[17]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 86,265,739.19, showing a decrease of 4.49% from CNY 90,322,193.27 in 2017[17]. - The net cash flow from operating activities for 2018 was CNY 133,612,108.47, down 32.12% from CNY 193,773,170.58 in 2017[17]. - The total assets at the end of 2018 were CNY 1,470,201,183.43, a 62.13% increase from CNY 906,784,989.29 at the end of 2017[18]. - The net assets attributable to shareholders at the end of 2018 were CNY 919,067,528.47, reflecting a significant increase of 148.27% from CNY 370,187,117.56 at the end of 2017[18]. - The basic earnings per share for 2018 was CNY 1.53, a slight increase of 2.00% from CNY 1.50 in 2017[18]. - The weighted average return on equity for 2018 was 22.18%, down from 29.98% in 2017, indicating a decrease of 7.80%[18]. - The company achieved total revenue of ¥1,255,047,658.50, representing a year-on-year growth of 43.74%[34]. - Operating profit reached ¥131,238,760.16, with a year-on-year increase of 6.08%[34]. Profit Distribution - The company reported a profit distribution plan of 7.50 RMB per 10 shares (including tax) based on a base of 90,000,000 shares, with no bonus shares issued[5]. - The company has a cash dividend policy in place, with a proposed cash dividend of RMB 7.50 per share for 2018, totaling RMB 67.5 million, representing 62.10% of the net profit attributable to ordinary shareholders[108]. - The company plans to distribute a cash dividend of RMB 7.50 per 10 shares, totaling RMB 67,500,000, which represents 100% of the total profit distribution[111]. - The total distributable profit for the year is RMB 247,919,224.31, indicating a strong cash flow position[111]. - No bonus shares or capital reserve transfers to increase share capital will be issued for the year 2018[111]. Business Operations and Strategy - The company emphasizes the importance of risk awareness regarding industry regulations, drug bidding, rising production costs, and the need for new product development and market promotion[5]. - The company has not experienced any changes in its main business operations or controlling shareholders since its listing[16]. - The company is a leading manufacturer of cephalosporin raw materials, with significant market share in products like cefalexin, cefradine, and cefaclor[33]. - The company is the largest producer of alpha-keto acid raw materials in China and a key supplier for Fresenius Kabi[33]. - The company maintains a "production based on sales" model, adjusting production plans monthly based on sales and inventory[30]. - The pharmaceutical industry is characterized as a weakly cyclical sector, with stable demand driven by economic growth and aging population[31]. - The company is focusing on new product development and an integrated "raw materials + formulations" strategy to sustain growth[34]. Research and Development - The company has invested in R&D, with three generic drug products entering the consistency evaluation BE testing phase during the reporting period[42]. - Research and development expenses amounted to 46,209,487.45 yuan, reflecting a 12.80% increase compared to the previous year[63]. - The company plans to accelerate R&D efforts in 2019, aiming to submit applications for two products' consistency evaluations and two new products' production registrations in China[91]. - The company has allocated 200 million CNY for research and development in the upcoming year, which is a 30% increase from the previous year[125]. Market and Sales - Domestic sales reached ¥1,229,009,778.48, making up 97.93% of total revenue, with a year-on-year increase of 48.50%[49]. - The revenue from pharmaceutical manufacturing accounted for 100% of total revenue, with a significant contribution from formulations at ¥935,137,746.30, which grew by 85.59% year-on-year[49]. - The company's sales volume of formulations in 2018 reached 94,297.34 million units, a year-on-year increase of 0.73% compared to 2017[53]. - The total sales amount from the top five customers was 441,264,870.42 yuan, accounting for 35.16% of the annual total sales[59]. Compliance and Governance - The company has established a comprehensive corporate governance structure to protect shareholder and creditor rights[162]. - The company emphasizes employee rights protection and has implemented a detailed human resources management system[163]. - The company has committed to ensuring the accuracy and completeness of the IPO prospectus, taking legal responsibility for any false statements or omissions[122]. - The company will actively communicate and compensate investors in case of any legal violations recognized by regulatory authorities[123]. Environmental and Social Responsibility - The company has implemented a wastewater treatment facility with a capacity of 1000 tons per day, ensuring compliance with national wastewater discharge standards[171]. - The company has achieved ISO14001 certification, demonstrating its commitment to environmental protection and sustainable practices[166]. - The company has invested 20 million yuan in poverty alleviation projects, specifically in the "Mountain-Sea Cooperation" initiative, supporting local enterprises and communities[169]. - The company actively participates in social welfare activities, including the establishment of a leukemia assistance fund in collaboration with the local Red Cross[167]. Risks and Challenges - The company faces risks from industry regulation changes, which may increase operational costs and negatively impact performance if strategies are not adjusted accordingly[96]. - Rising production costs are anticipated due to increases in raw material prices, labor costs, and the need for upgrades in quality management systems[98]. - New product development faces risks due to stringent regulatory requirements and long approval cycles, which may affect market acceptance and profitability[99]. - Environmental and safety risks are present due to the nature of chemical pharmaceutical production, with potential penalties for non-compliance with regulations[100].